• 1
    Parkin D, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 82741.
  • 2
    Beskow AH, Gyllensten UB. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 2002; 101: 52631.
  • 3
    Arias-Pulido H, Joste N, Wheeler CM. Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. Genes Chromosomes Cancer 2004; 40: 27784.
  • 4
    Terai M, Burk RD. Identification and characterization of 3 novel genital human papillomaviruses by overlapping polymerase chain reaction: candHPV89, candHPV90, and candHPV91. J Infect Dis 2002; 185: 17947.
  • 5
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 6
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796802.
  • 7
    Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001; 94: 711716.
  • 8
    Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, Stern PL. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1995; 1: 46470.
  • 9
    Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004; 13: 19518.
  • 10
    Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991; 352: 7235.
  • 11
    Gregoire L, Lawrence WD, Kukuruga D. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer 1994; 57: 5047.
  • 12
    Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Association between HLA DQB1*03 and cervical intra-epithelial neoplasia. Mol Med 1995; 1: 16171.
  • 13
    Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 1998; 25: 32937.
  • 14
    Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996; 67: 595602.
  • 15
    Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999; 60: 33742.
  • 16
    Apple RJ, Erlich HA, Klitz W, Manos M, Becker TM, Wheeler CM. HLA DR-DQ association with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994; 6: 15762.
  • 17
    Helland A, Olsen AO, Gjøen K, Akselsen HE, Sauer T, Magnus P, Dale AB, Rønningen KS. An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women. Int J Cancer 1998; 76: 1924.
  • 18
    Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001; 93: 81722.
  • 19
    Hildeseim A, Wang S. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89: 22940.
  • 20
    Poljak M, Brencic A, Seme K, Vince A, Marin IJ. Comparative evaluation of first- and second-generation Digene Hybrid Capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999; 37: 7967.
  • 21
    Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P. Comprehensive study of several general and type specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996; 34: 7457.
  • 22
    Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003; 12: 47784.
  • 23
    Van Der Zwan A, Griffith B, Rozemuller E, Williams T, Tilanus MGJ. Sequence-based typing for HLA-DQB1 strategy for ABI sequencing equipment.
  • 24
    Fu Y, Liu Z, Lin J, Chen W, Jia Z, Pan D, Xu A. Extensive polymorphism and different evolutionary patterns of intron 2 were identified in the HLA-DQB1 gene. Immunogenetics 2003; 54: 7616.
  • 25
    Dean J, Dean A, Burton J. Public domain software for epidemiology and disease surveillance. WHO AIDS series. 1990.
  • 26
    Xiang YB, Gao YT, Wang TJ. Application and comparison of meta and pooled analysis in the study of cancer epidemiology. Chin J Oncol 1999; 21: 3548.
  • 27
    Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389402.
  • 28
    Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000; 9: 175373.
  • 29
    Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26: 28391.
  • 30
    Delano WL. The PyMOL molecular graphics system (2002) on world wide web 2002.
  • 31
    Wu Y, Chen Y, Li L, Yu G, Zhang Y, He Y. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol, in press
  • 32
    Baas A, Gao X, Chelvanayagam G. Peptide binding motifs and specificities for HLA-DQ molecules. Immunogenetics 1999; 50: 815.
  • 33
    Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19: 15.
  • 34
    Van Muyden RC, Ter Harmsel BW, Smedts FM, Hermans J, Kuijpers JC, Raikhlin NT, Petrov S, Lebedev A, Ramaekers FC, Trimbos JB, Kleter B, Quint WG. Detection and typing of human papillomavirus in cervical caricinomas in Russian women: a prognostic study. Cancer 1999; 85: 201116.
  • 35
    Mikaelsdottir EK, Benediktsdottir KR, Olafsdottir K, Arnadottir T, Ragnarsson GB, Olafsson K, Sigurdsson K, Kristjansdottir G, Lmsland AK, Ögmundsdottir HM, Rafnar T. HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996. Gynecol Oncol 2003; 89: 2230.
  • 36
    Neuman RJ, Huettner PC, Lina L, Mardis ER, Duffy BF, Wilson RK, Rader JS. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gyneocol 2000; 95: 13440.
  • 37
    Glew SS, Duggan-Keen M, Ghosh AK, Ivinson A, Sinnott P, Davidson J. Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer. Hum Immunol 1993; 37: 15764.
  • 38
    Wank R, Meulen JT, Luande J. Cervical intraepithelial neoplasia, cervical carcinoma and risk for patients with HLA-DQB1*0602, *0301,*0303 alleles. Lancet 1993; 341: 1215.
  • 39
    Maciag PC, Schlecht NF, Souza PSA, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000; 9: 118391.
  • 40
    Maciag PC, Schlecht NF, Souza PSA, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis 2002; 186: 16472.
  • 41
    Dehaghani AS, Amirzargar A, Farjadian S. HLA-DQB1 alleles and susceptibility to cervical squamous cell carcinoma in Southern Iranian patients. Pathol Oncol Res 2002; 8: 5861.
  • 42
    Mehal WZ, Lo YM, Herrington CS, Evans MF, Papadopoulos MC, Odunsi K, Ganesan TS, McGee JOD, Bell JI, Fleming KA. Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis. J Clin Pathol 1994; 47: 107781.
  • 43
    Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988; 332: 84550.
  • 44
    Johansen BH, Jensen T, Thorpe CJ, Vartdal F, Thorsby E, Sollid LM. Both a and b chain polymorphisms determine the specificity of the disease-associated HLA-DQ2 molecules, with b chain residues being most influential. Immunogenetics 1996; 45: 142150.
  • 45
    Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 130810.
  • 46
    Xu AL, van Eijk MJT, Park C, Lewin HA. Polymorphism in BoLA-DRB3 exon 2 correlates with resistance to persistent lymphocytosis caused by bovine leukemia virus. J Immunol 1993; 151: 697785.
  • 47
    Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 6908.